Search | Clinical Trials Finder

Conditions: GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML), Multiple Myeloma (MM), Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell), Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)
Interventions: milatuzumab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
Interventions: extracorporeal photopheresis; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
Interventions: Prednisone; Drug
Lead sponsor: John Levine; Other
Eligibility: Up to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more

Conditions: Graft Vs Host Disease
Interventions: Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone, Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil; Drug
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 9
States / cities: Indianapolis, Indiana • Kansas City, Missouri • Hackensack, New Jersey + 6 more

Conditions: Graft-Versus-Host Disease(GVHD)
Interventions: 5-Azacytidine; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Wound, Ulcer, Burns
Interventions: Negative pressure wound therapy coupled with instillation, Standard Negative Pressure Wound Therapy; Device
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Healing of Extraction Socket
Interventions: Extraction with socket graft; Procedure
Lead sponsor: Boston University; Other
Eligibility: 20 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Burns, Trauma, Venous Ulcers
Interventions: MIST Therapy, Standard of care; Device · Other
Lead sponsor: Celleration, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Interventions: RAD001, MMF; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri

Conditions: Systemic Inflammatory Response Syndrome, Acute Kidney Injury
Interventions: coronary artery bypass grafting using cardiopulmonary bypass; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: ACL - Anterior Cruciate Ligament Rupture
Interventions: Bio ACL, Control; Other
Lead sponsor: Andrews Research & Education Foundation; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Gulf Breeze, Florida

Conditions: Kidney Transplantation in Highly Sensitized Patients
Interventions: Imlifidase administered in the ConfIdeS study, Best available treatment administered in the ConfIdeS study; Drug · Other
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: Not listed
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 9 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Biospecimen Collection, Optical Coherence Tomography, Spirometry, Survey Administration, Digital Photography, Quality-of-Life Assessment, Medical Chart Review; Procedure · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Gainesville, Florida • Tampa, Florida • Bethesda, Maryland + 4 more

Conditions: Liver Diseases, Surgery, Transplant; Failure, Liver
Interventions: Declined liver in Normothermic Machine Perfusion (NMP), Standard cold preservation of liver; Device · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Skin Flora Contamination
Interventions: InteguSeal* skin sealant and standard surgical preparation, Standard preoperative skin preparation; Procedure · Other
Lead sponsor: Kimberly-Clark Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: Pediatric Hematologic Malignancies
Interventions: Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Up to 30 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Neoplasm Metastasis
Interventions: methotrexate, Cyclosporin; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 10 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronary Artery Disease
Interventions: ComboMap XT Guidewire, 'SPY' NIRF During CABG; Device · Procedure
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Graft vs. Host Disease
Interventions: Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hypertension, Portal, Ascites
Interventions: Gore® Viatorr® Endoprosthesis with controlled expansion, Large Volume Paracentesis with albumin infusion; Device · Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Leukemia, Myeloma, Myeloproliferative Diseases
Interventions: Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire; Drug · Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions: azacitidine, donor lymphocyte infusion; Drug · Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 29 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Mucosal Erosion, Gingival Recession
Interventions: Visual Analog scale (VAS) questionnaire, Vacuum-formed retainer (VFR) technique, 3-D printed acrylic resin stent (3DS) technique, Flowable resin composite stent (FRC) technique, Photographs of the patient's palate, Measuring graft dimensions, Chairside Polymer Stent; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Congenital Pseudarthrosis of Tibia
Interventions: NVD003, Iliac Crest Bone Graft; Biological · Procedure
Lead sponsor: Novadip Biosciences; Industry
Eligibility: Up to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • Loma Linda, California • Baltimore, Maryland + 1 more

Search by objective public record fields.

Phase I Study of Milatuzumab for Graft Versus Host Disease

Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease

Pediatric GVHD Low Risk Steroid Taper Trial

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)

Coupling Negative Pressure Wound Therapy With Instillation

The Impact of a Known Bioactive Agent on the Resolution of Alveolar Socket Preservation

Split Thickness Donor Site Healing With MIST Study

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

Platelets as Regulators of Inflammation in Cardiac Surgery

Bio ACL Reconstruction Amnion Collagen Matrix Wrap and Stem Cells

Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys

Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study

RESTORE Declined Livers Study

Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora Contamination

Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies

Stem Cell Transplantation for Metastatic Solid Tumors

Correlation Study of Imaging Data Acquired During CABG With Data Acquired in the Cath Lab

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

Patient-reported Outcomes of Donor Site Healing Using Different Palatal Protection Techniques

A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.